GO
Loading...

Enter multiple symbols separated by commas

Actavis Inc

More

  • Valeant raises outlook after completing purchase of Salix Wednesday, 29 Apr 2015 | 6:43 AM ET

    LAVAL, Quebec— Valeant Pharmaceuticals International Inc. said Wednesday it turned a profit in the first quarter, and the Canadian drugmaker raised its forecasts for the year after completing more acquisitions. The company reported a profit of $73.7 million, or 21 cents per share, after it lost $22.6 million, or 7 cents per share, a year ago. The Laval, Quebec- based...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • April 22- Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV. Meanwhile, Canonsburg, Pennsylvania- based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter...

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • Teva offers to buy Mylan in $40.1B cash-and-stock deal Tuesday, 21 Apr 2015 | 9:14 AM ET

    TRENTON, N.J.— Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators. If Israel- based Teva Pharmaceutical Industries Ltd. succeeded, the combination would...

  • NEW YORK, April 13- Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer's drug in favor of a pricier extended-release version, a move that New York's attorney general has said would suppress generic competition. New York Attorney General Eric Schneiderman filed an antitrust lawsuit against Dublin- based Actavis...

  • Zoetis agreed with Pershing Square and Sachem Head Group in February to add two independent directors. The agreement prevents Pershing Square from raising its stake in Zoetis to above 12.5 percent and soliciting any takeover offers for the company or its units. Pershing Square was Zoetis's largest shareholder as of Feb. 3 with an 8.35 percent stake, according...

  • April 13- Animal health products company Zoetis Inc appointed a second director to its board under its agreement with Bill Ackman's hedge fund Pershing Square Capital Management. Zoetis said on Monday that it added Actavis Plc Executive Chairman and former chief executive Paul Bisaro to its board. Zoetis had appointed William Doyle, a Pershing Square...

  • Ackman's $20 billion Pershing Square Capital Management hedge fund began building up the $3.3 billion stake, only months after its vocal effort to help Valeant buy Botox-maker Allergan failed, a source familiar with the investment told Reuters. His Pershing Square has notched big wins at railway firm Canadian Pacific and shopping mall operator General...

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • *Brent crude ends above $61 on conflict in Libya. NEW YORK, March 3- U.S. stocks followed other equities markets lower on Tuesday, with major indexes pulling back from record highs as soft auto sales raised doubts about the U.S. economy, while the dollar fell from an 11- year peak versus a basket of currencies. "The air gets a little thin up at new highs and you need a driver...

  • *Actavis launches $21 billion bond deal. *Exxon Mobil to sell $7 billion in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record, according to Thomson Reuters unit IFR.

  • *Brent crude climbs near $61 on conflict in Libya. NEW YORK, March 3- U.S. stock prices fell on Tuesday, with the Dow Jones industrial average and the Standard& Poor's 500 pulling back from record highs, while the dollar fell from an 11- year peak versus a basket of currencies. "The air gets a little thin up at new highs and you need a driver to keep it going, and one of the...

  • *Actavis launches $21 bln bond deal. *Exxon Mobil to sell $7 bln in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record according to Thomson Reuters unit IFR.

  • *Brent crude climbs above $61 on conflict in Libya. NEW YORK, March 3- U.S. stock prices fell on Tuesday, with the Dow Jones industrial average and Standard& Poor's 500 receding from their record highs, while the dollar fell from its 11- year peak versus a basket of currencies. "The market is naturally settling in, taking a breather until the scales tip either way to...

  • NEW YORK, March 2- U.S. Pharmaceutical company Actavis on Monday was marketing bonds that are expected to total $22 billion, the second largest amount ever sold by a corporate borrower. "Corporate deals are weighing on the market, and we've heard of some allocation out of bonds into equities," said Sean Murphy, a Treasuries trader at Societe Generale in New York.

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis Plc holds the commercial license to the device, Liletta. Actavis and Medicines360 expect the device to be available for use in the United States by the second quarter of 2015.. The Actavis device will compete in the $1 billion global market for UIDs, said Michael WaterHouse, an analyst at brokerage Morningstar.

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...